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Abstract
Background: T helper epitopes are necessary for the induction of high titers of antigen-specific
IgG antibodies. We are interested in the epitope modification of intact proteins as a method to
enhance their immunogenicity for the generation of recombinant protein-based vaccines.
Results: Hartley strain guinea pig T cell epitopes were mapped for two related bacterial proteases.
Two T cell epitopes were found in one of the proteases, while a comparatively reduced
immunogenicity protease had no detectable T cell epitopes. A T cell epitope sequence homologous
to the immunogenic protease was created in the less immunogenic protease by changing a single
amino acid. Proliferative responses to the whole protein parent enzyme were two-fold higher in
splenocyte cultures from variant-immunized animals. We found that the single amino acid change
in the variant resulted in a protein immunogen that induced higher titers of antigen-specific IgG
antibody at low doses and at early time points during the immunization protocol. The serum from
parent- and variant-immunized guinea pigs cross-reacted at both the protein and the peptide level.
Finally, animals primed to the variant but boosted with the parent enzyme had higher levels of
antigen-specific IgG than animals immunized with the parent enzyme alone.
Conclusions: With a single amino acid change we have introduced a T cell epitope into a
comparatively low-immunogenic enzyme and have increased its immunogenicity while retaining the
enzyme's original proteolytic function. The ability to immunomodulate proteins while leaving their
function intact has important implication for the development of recombinant vaccines and protein-
based therapeutics.
Background
High affinity humoral immune responses to most protein
antigens require cognate interactions between antigen-
specific T and B cells. Antigen-specific T cells encounter
antigen presented by dendritic cells that migrate to the
paracortical regions of draining lymph nodes after initial
antigen contact [1]. Only dendritic cells have the capacity
to induce activation in resting peripheral T cells [2,3].
Once activated, differentiated T helper cells contact anti-
gen-specific B cells and provide signals for B cell differen-
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tiation via CD154-CD40 interactions, as well as by the
production of cytokines [4–6]. Consistent with this gener-
al understanding of the induction of antibody responses
to protein immunogens, good antibody responses to syn-
thetic peptide-epitope constructs have been shown to de-
pend on the presence, orientation, and multiplicity of the
T cell epitope in the construct [7–11]. As a confirmation
of this finding with synthetic epitope constructs, most
protein immunogens studied to date contain multiple T
cell epitopes, for example [12,13].
T helper epitopes have become common components of
synthetic vaccine constructs due to their ability to provide
immunological help for both humoral and cell-mediated
responses [11,14–16]. T cell epitopes that can induce
helper activity by binding to a wide range of HLA-DR alle-
les have been developed by a number of investigators us-
ing various antigen systems [17–19]. T cell epitopes that
have the property of binding across a wide range of HLA-
DR haplotypes are necessary for the construction of syn-
thetic vaccines that would be useful in the human popu-
lation as a whole. DNA- and peptide-based vaccines have
become popular due to the comparative ease of construc-
tion, the circumvention of potential safety issues around
attenuated organisms, and for their potentially enhanced
immunogenicity compared to heat-killed and subunit
vaccines [20–22]. DNA vaccines have the added attraction
of efficiently priming both humoral and cytotoxic cell re-
sponses, a property largely lacking in subunit and attenu-
ated organism vaccines. Priming of cytotoxic cell
responses is necessary for the design of therapeutic cancer
vaccines, as well as for viral vaccines. Multiple antigen
peptide vaccines can also be designed to contain T and B
epitope regions from numerous protein antigens derived
from a complex infectious agent which could therefore
confer broad protection without the potential dangers of
an attenuated whole organism vaccine [16]. However, it is
of note that occasionally a well-designed peptide-based
vaccine can elicit strong antibody responses to the syn-
thetic immunogen that do not confer protection from the
parasite to which they were originally designed [23]. This
may be due to either the induction of an inappropriate an-
tibody isotype in the mouse strain used, or to an inade-
quate overall response.
While subunit vaccines have their inherent shortcomings,
they carry the added benefit of potentially inducing com-
plex antibody responses to multiple sites on the whole
protein immunogen. Subunit vaccines are of interest in
the prevention of parasite infection [24] and for a variety
of infectious diseases [25]. An ideal subunit vaccine for
the induction of protective antibody responses would be
a protein from the disease-causing organism that was
minimally modified from its original structure to retain a
variety of potential B cell epitopes. In addition, the modi-
fied subunit vaccine would be designed to be highly im-
munogenic by the addition of promiscuous T cell
epitopes. To this end, we have characterized the immune
response of partially outbred Hartley strain guinea pigs to
two related bacterial proteases. The two bacterial enzymes
studied represent important industrial enzymes used in a
number of applications, including serving as an additive
for laundry products, and animal feed processing. These
enzymes have been well characterized as to their activity
and specificity by us and by others [26,27]. While these
two proteins are approximately 60% homologous at the
amino acid sequence [26], one of the proteases was signif-
icantly less immunogenic than the other. Reduced immu-
nogenicity was characterized as significantly lower titers of
antigen-specific IgG when animals were immunized with
the same amount of the enzymes. We determined the T
cell epitopes in both of the proteases using 15-mer pep-
tides and splenocytes from immunized animals. In order
to be classified as an epitope, the average proliferative re-
sponse to a peptide had to reach a stimulation index of
3.0. Two regions met our criteria as epitopes in the immu-
nogenic protease. We tested a total of 20 guinea pigs and
found no epitope regions in the less immunogenic pro-
tease. A sequence comparison of the enzymes in the T cell
epitope regions revealed that a single amino acid change
could confer a T cell epitope onto the less-immunogenic
protease. This variant was constructed, and was found to
be a functional and stable protease. Immunization of
Hartley strain guinea pigs showed that this single amino
acid change created a T cell epitope where there was no de-
tectable epitope before, and the presence of this epitope
correlates with an improved immunogenicity in the vari-
ant. Finally, we show that the variant induces broadly
cross-reactive IgG antibodies, and that priming of animals
with the variant protein results in higher titers of antigen-
specific antibody upon subsequent immunization with
the parent enzyme.
Results
IgG antibody titers from B. lentus subtilisin and BPN' 
Y217L guinea pig immunizations
Female Hartley strain guinea pigs were immunized with
two related bacterial proteases, B. lentus subtilisin and
BPN' Y217L. These two bacterial enzymes share 60% ho-
mology at the amino acid level. They are also comparable
in their proteolytic activity and specificity [26,27]. Ani-
mals were immunized every two weeks with a 20 ug dose
of enzyme in adjuvant. Serum samples were drawn prior
to each immunization over a ten-week period. Serum
samples were tested for antigen-specific IgG antibodies by
ELISA. Titers were calculated for each animal's antibody
response. Averages for four animals are presented in Fig-
ure 1. The titers over time are presented as serum dilution
(B) and as Log2 titers (A). Immunization with B. lentus
subtilisin induced higher titers of antigen-specific IgGBMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/2
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than BPN' Y217L after 4 weeks. The response to B. lentus
subtilisin reached maximal levels by about 6 weeks. At the
6 to 10 week time points, titers leveled off and the average
titers induced by immunizations with B. lentus subtilisin
were about 10 fold higher than BPN' Y217L. B. lentus sub-
tilisin remained more immunogenic at doses from 1 to 20
µg. (not shown). Overall maximum titer levels vary, but
the difference in immunogenicity between B. lentus sub-
tilisin and BPN' Y217L has been seen in three separate
guinea pig studies. This difference in immunogenicity has
been noted by others using an intratracheal method of im-
munization [28,29].
T cell epitope mapping of B. lentus subtilisin and BPN' 
Y217L
Splenocytes from immunized guinea pigs were used to de-
termine the position of T cell epitopes in B. lentus subtili-
sin and BPN' Y217L. 10 animals were tested for each
immunogen. 15-mer peptides offset by 3 amino acids
were used at 5 µM, and were tested at least in duplicate for
each immunized animal. Peptides eliciting a 3-fold or
higher average proliferative response over the background
response were considered T cell epitopes. These epitopes
are shown in bold in Figure 2. Two T cell epitopes were
found in 5 of the 10 guinea pigs immunized with B. lentus
subtilisin, but none meeting the criteria of a three-fold in-
crease in proliferation over the background were found in
the 10 animals immunized with BPN' Y217L in this exper-
iment (p = 0.01; non-parametric Student' t-test). Notably,
the first B. lentus subtilisin epitope has an analogous re-
gion in BPN' Y217L. only the first amino acid is different.
It was hypothesized that if the first valine in the analogous
BPN' Y217L sequence was changed to an isoleucine, a T
cell epitope analogous to the one found in B. lentus sub-
tilisin would be created. A modified BPN' Y217L V72I en-
zyme (GP002) was prepared with this single amino acid
change (Figure 3).
Enzyme activity and stability
Enzymatic activity has been implicated as a source of the
allergenic property of Der p1, the major dust mite allergen
[30–32]. In order to account for this variable, the enzy-
matic activity of the variant protease GP002 was com-
pared BPN' Y217L. Proteolytic activity was determined in
a standard sAAPF hydrolysis assay. The activity of GP002
was found to be approximately 80% of the parent BPN'
Y217L enzyme (Figure 4). Another factor that could influ-
ence the immunogenicity of a proteolytic enzyme is the
relative stability of the protease. If the protease remains
active for a longer period of time, any effects of the activity
would be comparatively magnified. The half-lives of both
enzymes were tested at 37°C over a 74-hour time period
to assess relative stability. The assay was performed at
physiologic pH = 7.3. At various time points, the proteo-
lytic activity remaining in the samples were tested. At 37
degrees and a pH of 7.3, BPN' Y217L has a half-life fifty-
five hours longer than GP002. These results indicate that
the two enzymes have comparable stability and efficacy.
Comparable enzymatic activity and stability suggest that
the variant molecule has a similar tertiary configuration as
the parent.
T-cell epitope mapping BPN' Y217L versus GP002
Hartley strain guinea pigs were immunized with 5 µg per
dose of either BPN' Y217L or GP002 every two weeks. Af-
ter 6 weeks epitope mapping was performed as described
using the BPN'Y217L 15-mer PepSet and splenocytes
from the primed animals (Figure 5). In addition, prolifer-
Figure 1
Guinea pig antigen-specific IgG responses to B. lentus subtili-
sin and BPN' Y217L. Two groups of four Hartley Guinea pigs
were immunized with 20 µg of protease five times over a 10-
week period. Serum samples were taken every two weeks.
Antibody titers were determined by ELISA. Titers were cal-
culated by determining the ODs at 405 nm where y = 0.5,
using a regression analysis of titer data for each animal. Fig-
ure 1A shows the average titers and standard deviations in a
log base 2 format, Figure 1B represents the same data in a
base 10 format.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/2
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ative responses to the intact inactivated BPN' Y217L en-
zyme were tested. Immunization with GP002 resulted in
an increased proliferative response to whole protein
BPN'Y217L. The average stimulation index (proliferative
response to enzyme/proliferation in control cultures) to
20 ug of whole protein was 23, versus an average stimula-
tion index of 11 for the BPN' Y217L-immunized spleno-
cytes. Epitope mapping with splenocytes from BPN'
Y217L immunized guinea pigs revealed no epitope re-
gions with an average stimulation index of 3.0 in any of
the animals tested (n = 5). This is consistent with our pre-
vious results for this enzyme, using splenocytes from ani-
mals immunized with 20 ug per dose of enzyme every two
weeks for 10 weeks. Four out of five of the GP002 immu-
nized animals responded with stimulation indices of
greater than 3.0 to the modified epitope region in BPN'
Y217L (peptide #25). The average response to this peptide
was approximately 4.0. Peptide #25 is offset from the T
cell epitope described in B. lentus by 2 amino acids. This is
a result of creating linear 15-mers from the two sequences
where there is a 2 amino acid contraction in B. lentus sub-
tilisin as compared to the BPN' Y217L sequence. Primed
splenocytes from guinea pigs also respond to peptide #24
that is 3 amino acids offset towards to N-terminus, and
subsequently overlaps with the T cell epitope region. The
creation of a T cell epitope in BPN' Y217L also resulted in
the display of a complex set of weak epitopes in the mol-
ecule. Peptides #25 and #75 induced average responses
over the 5 animals that reached an S.I. of approximately
3.0. Five peptide regions induced average responses of ap-
proximately 2.5. Therefore, creation of a strong T cell
epitope in this protein initiates an immune response that
leads to the diversification of T cell responses to other re-
gions of the molecule.
Antibody titers with BPN' Y217L and GP002
In order to test whether the modified enzyme could in-
duce higher titers of antigen-specific IgG now that it car-
ried a strong T cell epitope, guinea pigs were immunized
with increasing doses of BPN' Y217L or GP002. Serum
samples were taken every two weeks and titers were calcu-
lated. Average titers for four animals per group are shown
in Figure 6. Immunization with the modified enzyme re-
sulted in higher titers of antigen-specific IgG at early time
points in the immunization protocol (Figure 6a). At later
points during the immunization protocol, lower doses of
the variant induced higher titers than the parent (Figure
6b, c, d). At four weeks, the 20 ug dose GP002 induced an
average serum dilution titer of 5,000 versus no detectable
IgG in the BPN' Y217L immunized animals. This differ-
ence between GP002 and BPN' Y217L has a p value of
0.03 when calculated using a two-tailed, non-parametric
Figure 2
Guinea pig T cell epitopes in B. lentus subtilisin and BPN' Y217L. Hartley strain guinea pigs were immunized with either B. lentus
subtilisin or BPN' Y217L. Splenocytes from immunized Hartley Guinea pigs were incubated in vitro with 15 mer peptides
describing the sequence of the immunizing protein as described in the material and methods section. An epitope region was
assigned if the T cell proliferation to a peptide reached an average SI of 3.0. Two major T cell epitopes were found in B. lentus
subtilisin (underlined). No T cell epitopes meeting our criteria were found in BPN' Y217L. The first B. lentus subtilisin epitope
has a very similar region in BPN' Y217L (in brackets) which contains the single amino acid change of I 72 V.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/2
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Student's t-test. By ten weeks, the difference is no longer
detected at the 5 and 20 µg doses but there is still a ten-
fold difference in titers at the lowest dose.
Linear B Cell Epitopes BPN' Y217L v. GP002
A potential explanation for the increase in antibody titers
is that the modification in GP002 results in a conforma-
tionally distinct molecule with unique surface regions,
thereby increasing the total number of antibody binding
sites. Guinea pig serum samples from animals immunized
with 5 µg of enzyme were used to determine the position
of linear B-cell epitopes in BPN' Y217L (Figure 7). The se-
rum samples were drawn at 8 weeks, and whole protein
titers are shown in Figure 6. Serum samples from four an-
imals immunized with BPN' Y217L and four animals im-
munized with GP002 were tested on biotinylated 15-mer
peptides (offset by 5 amino acids). Serum was diluted
1:1000 for all tests. Guinea pig IgG was detected with
HRP-conjugated anti-IgG. The average optical densities
for each peptide were divided by the background. The av-
erage result for each peptide is shown. The linear B-cell
epitope regions recognized by both polyclonal serum
samples are similar. The amino acid modification in
GP002 would be in the region of peptides #13 to #16. If
the amino acid modification produced a B cell epitope at
this site, it does not cross-react onto the unmodified pep-
tide regions tested here. The regions of the BPN' Y217L
molecule detected in this assay are predicted external
loops (Dr. Richard Bott, Genencor International, personal
communication). The major regions recognized, peptides
#3 and 4, #17 and 18, and #46 and 47 are equivalently
recognized by both serum sets. Of the 29 regions of the
molecule showing an average two-fold increase in IgG
binding over the background, 17 of these regions are de-
tected more strongly by the GP002 sera. 5 peptide regions
are uniquely detected by the BPN' Y217L serum, and 7 are
uniquely recognized by the GP002 serum. There is a shift
in one epitope region from peptides #38–43 where the
GP002 antibody epitope runs from peptide 38 to peptide
Figure 3
Schematic representation of the parent and modified enzyme
variant. The first Guinea pig T cell epitope on B. lentus subtili-
sin has an analogous sequence (with a single amino acid
change) in BPN' Y217L which is not detected in our assay as
a T-cell epitope. A hybrid BPN' Y217L enzyme (GP002) was
designed which contains the B. lentus subtilisin epitope.
Figure 4
Proteolytic activity and stability of the variant GP002 as com-
pared to the parent enzyme. The variant enzyme, GP002,
was compared to BPN' Y217L for both proteolytic activity
and thermostability. Figure 4A shows proteolytic activity as
determined by a suc-AAFP-pNA hydrolysis assay. Figure 4B
shows the results of the thermostability test performed at
close to physiological conditions. Residual activity was deter-
mined over time, and the half-life was determined by linear
regression.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/2
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41, and BPN' Y217L's runs from peptide 40 to peptide 43.
This 10 amino acid shift forward indicates a slight differ-
ence in protein folding. This difference has little apparent
effect on the other antibody epitopes delineated by this
assay. This assay demonstrates that GP002-specific IgG
antibodies readily cross-react with BPN' Y217L linear an-
tibody epitopes.
BPN' Y217L and GP002 Priming Immunizations
It was of interest to determine whether increased titers of
IgG antibodies to BPN' Y217L could be induced by prim-
ing animals with the T cell epitope-containing variant.
Four sets of four guinea pigs were immunized with 5 µg of
enzyme over a six-week period in series. The animals were
immunized three times, once every two weeks. This proto-
col was chosen to correspond with the titer data presented
in Figure 6. Group A was immunized three times with
BPN' Y217L, Group B was immunized first with the
GP002, and then twice with BPN'Y217L. Group C was im-
munized the first two times with the GP002, and the third
time with BPN' Y217L.
Finally, Group D was immunized all three times with
GP002. Two weeks after the last immunization serum
samples were taken and ELISAs were performed to com-
pare titers. All ELISAs were performed using the parent en-
zyme, BPN' Y217L, as a plate coating reagent. Results
clearly show once again that immunization with GP002
induces over 10-fold higher levels of antigen-specific IgG
than the unmodified parent enzyme (Figure 8). The differ-
Figure 5
The introduction of a T cell epitope into the BPN' Y217L backbone results in a complex T cell epitope map. Two groups of five
guinea pigs were immunized with 5 ug of either the parent or variant enzyme every two weeks for a total of three immuniza-
tions. At eight weeks, spleens were removed and splenocytes were tested in vitro for proliferative responses to BPN' Y217L
peptides. The average proliferation is recorded above for each peptide across the five animals. Note that an epitope was cre-
ated for the BPN' Y217L peptide number 25, where the single amino acid change was effected. The proliferative response was
also boosted across the entire range of the enzyme.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/2
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ence between group A and D was highly significant (p <
0.01). In addition, a single immunization with the T cell
epitope modified variant GP002 is sufficient to induce
higher levels of parent-enzyme-specific IgG after subse-
quent immunizations with the unmodified parent en-
zyme. While the average titer increased by approximately
two-fold, the difference between group A and B was not
statistically significant. Each group contained only four
animals, with appreciable scatter in the individual re-
sponses. Two immunizations with GP002 prior to immu-
nizing with the parent enzyme did not improve the titers
as compared to a single priming immunization with
GP002. This result suggests that priming with the variant
enzyme can induce higher levels of cross-reactive IgG an-
tibodies than immunization with the unmodified variant
alone. This experiment also confirms that GP002 immu-
nized animals produce high titers of IgG that cross-react
on the whole BPN' Y217L molecule.
Discussion
We have shown that a single conservative amino acid
change in a bacterial subtilisin enzyme can create a strong
T cell epitope in our guinea pig model. Immunization of
guinea pigs with this modified variant results in an im-
proved cross-reactive immune response to the unmodi-
fied parent enzyme in both antigen-specific IgG antibody
production and T cell proliferative responses. The im-
proved immunogenicity of the variant was not related to
changes in the proteolytic capacity of the enzyme, because
the variant exhibited 80% of the activity of the parent en-
zyme. The introduction of a single T cell epitope apparent-
ly allowed for the diversification of T cell responses to the
protein because multiple epitopes were found in the BPN'
Y217L sequence after immunization of animals with the
variant (Figure 5). An increase in the complexity of the T
cell response is consistent with an increase in overall anti-
body titer to the enzyme, as more T cell helper activity is
potentially available. The antibody responses to the vari-
ant and parent enzymes were shown to be largely overlap-
ping, indicating that the increase in the antibody titers
seen were not due to the addition of a novel structure ca-
pable of being recognized by unique antibody specifici-
ties. This is shown by the last experiment where priming
with the variant enzyme increased antibody titers to the
parent enzyme upon subsequent immunizations.
It was of interest that the unmodified protease induces an-
tigen-specific IgG in the absence of detectable immunodo-
minant T cell epitopes. BPN' Y217L may possess weak T
cell epitopes that are below our limit of detection in our
cell culture assay. Our criterion for an epitope was an av-
erage stimulation index of 3.0. In addition, it is notable
that both of the immunogens tested display considerable
proteolytic activity. The proteolytic activity of the parent
enzyme could be responsible for inducing T cell inde-
Figure 6
Antibody titers of BPN' Y217L v. GP002 immunized Guinea
pigs. Guinea pigs were immunized with 1, 5, or 20 ug of BPN'
Y217L or GP002. Serum samples were taken every two
weeks over a ten-week time period. Dose responses are
shown for the 4, 6, 8 and 10 week samples. Average titers for
four animals per dose are shown.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/2
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pendent B cell differentiation via a number of different
mechanisms [33–35]. Finally, we have seen than both
chemically inactivated and an inactive variant of the par-
ent protease used in these experiments are incapable of in-
ducing IgG1 in a mouse model (data not shown). The
proteolytic activity of these molecules also acts as an adju-
vant for specific IgG production [36].
The ability to induce improved immune responses by the
subtle changes described here could have a number of po-
tentially vital applications. The use of a T cell epitope-
modified whole protein immunogen confers a number of
advantages. The first advantage is the priming of a diverse
immune response to the protein that allows the genera-
tion of both a complex and robust T helper responses, and
secondly the concomitant affinity maturation of the anti-
body response to naturally occurring antibody epitopes.
This is especially relevant to the design of subunit vaccines
for malaria and schistosomiasis where high titers of high
affinity antibodies are usually the best defence against in-
vading organisms [11,16,24]. Creating T cell epitopes in
expressed proteins has been demonstrated here for Hart-
ley strain guinea pigs, and for various inbred strains of
mice [37,38]. Interestingly, the introduction of T cell
epitopes from a hen-egg lysozyme or ovalbumin into
mouse TNF-alpha also resulted in an increased cross-reac-
tive antibody response in mice [38]. However, the protein
construct was no longer cytotoxic for L929 cells, suggest-
ing that the modified protein was not in the correct terti-
ary configuration. Incorrect tertiary configuration could
lead to the production of specific antibodies that do not
cross-react with the native molecule. T cell responses to
the variants were not well characterized. In this paper, and
in the report from Tsujihata [37] T cell epitopes were cre-
ated within the molecule of interest, without affecting the
activity of the enzyme. We created a naturally occurring T
cell epitope by comparison to a related protein. In addi-
tion, we found that the creation of a T cell epitope in BPN'
Y217L resulted in a complex pattern of T cell response to
the enzyme. The challenge of utilizing this technique for
the creation of subunit vaccines for the human popula-
tion will be to create T cell epitopes within a protein of in-
terest that will not have deleterious effects on the activity
or the stability of the protein of interest, and that would
be effective across a number of HLA-DR haplotypes [39].
The improved antibody response measured in this paper
was increased titers of guinea pig polyclonal IgG. We did
not measure potential differences in guinea pig IgG iso-
types. Changing the interaction of peptide, MHC class II
molecules, T cell receptors and other antigen-presenting
cell specific ligand interactions to foster stronger, higher
affinity T cell signalling has been shown in mice to skew T
cell differentiation from Th2 to Th1-like patterns [40–50].
Differences in Th-differentiation patterns have down-
stream effects on the type of immune response mounted,
and in particular on the isotypes of antibody expressed.
This has been well documented for mice and humans, but
Figure 7
Linear B cell epitopes recognised by sera from guinea pigs immunized with the parent and the variant enzyme. Serum samples
from animals immunized with the parent and the variant were used to detect IgG binding to peptides describing the sequence
of BPN' Y217L. All sea was diluted 1:1000. Binding was detected with anti-guinea pig IgG. Absorbance results are averaged for
four animals in each group.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/2
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less is known about Th differentiation in Hartley strain
guinea pigs.
In our system, we cannot distinguish if the amino acid
change we have created has its effects on binding to the
guinea pig MHC, interaction with the T cell receptor, or
more efficient processing of the epitope from the protein
precursor [51]. Any or all of these mechanisms could con-
tribute to the enrichment for peptide-specific proliferative
responses seen in vitro.
The ability to up regulate antibody and T cell responses to
whole protein immunogens by the modification of T cell
epitopes suggests that the converse would also be possi-
ble. Down regulation of T cell responses to functionally
intact enzymes would have obvious implications for both
existing and potential protein therapeutics.
Conclusions
The immunogenicity of an enzyme can be increased,
while maintaining the majority of its stability and proteo-
lytic activity, by incorporating a single amino acid change.
The variant enzyme was found to have a major T cell
epitope where none existed in the parent. In addition to
the increased cellular response, humoral responses were
increased at low doses, and as well for high doses early in
the immunization schedule. Enhancing the T cell re-
sponse to an enzyme, in addition to the humoral re-
sponse, has applications in the construction of
recombinant vaccines as well as in protein-based thera-
peutics.
Materials and Methods
Protease enzymes
GP002 was created by site-directed mutagenesis of the se-
quence of BPN' Y217L and expressed in B. subtilisn. En-
zymes were purified from fermentation broths utilizing
the BioCAD 700E system (Perceptive Biosystems, Foster
City, CA) using POROS HS/M resin (Perceptive Biosys-
tems, Foster City, CA) on porous polystyrene beads, and
was stored as stock solutions at 20 mg/ml in 20 mM MES,
pH 5.5 with 1 mM CaCL2 at -20°C.
Enzyme activity and stability measurements
Proteolytic activity was measured by hydrolysis of the sub-
strate succinyl-AAPF-p-nitroanilide (suc-AAPF-pNA). Seri-
al dilutions of the proteases were made in 100 mM Tris
buffer, pH 8.6, containing 10 mM CaCl2. Enzyme activity
was measured at 25°C in 100 mM Tris/HCl, pH 8.6 con-
taining 1.6 mM suc-AAPF-pNA (Bachem Bioscience, Tor-
rance, CA), 0.0005% Tween-80 and 1% DMSO by
monitoring the absorbance change at 410 nm using a
spectrophotometer. Each dilution of enzyme was tested in
triplicate. Three dilutions were tested for each enzyme. Ac-
tivity was then determined by linear regression, and is re-
ported as OD units/mg enzyme.
Comparative thermostability was determined for BPN'
Y217L and GP002 by incubating the enzymes (0.5 ppm)
at 37°C in 50 mM TES buffer, pH 7.3 containing 0.0005%
Tween-80. Aliquots of the enzyme solutions were re-
moved over time, diluted and assayed for activity using 1
mM suc-AAPF-pNA substrate in 100 mM Tris pH 8.6 con-
taining 0.0005% Tween-80. The half-lives of the enzymes
were then calculated using a linear regression.
Immunization protocols
1. BPN' Y217L, B. lentus subtilisin, and GP002 immunizations
Guinea pig immunizations were outsourced to EL Labs in
Santa Cruz, CA. Female Hartley outbred guinea pigs
weighing 200–600 grams were used in all studies. There
were three or four dosages of the appropriate enzyme and
for each dosage there were four animals immunized. Each
Figure 8
Priming of IgG responses to the parent enzyme, BPN' Y217L,
by the T cell epitope modified variant GP002. Four sets of
four Guinea pigs were immunized with 5 ug of enzyme on
various schedules. All groups were immunized three times,
once every two weeks. Group A was immunized all three
times with BPN' Y217L. Group B was immunized first with
GP002, and then twice with BPN' Y217L. Group C was
immunized the first two times with GP002, and the third
time with BPN' Y217L. Finally, Group D was immunized all
three times with GP002. After testing the sera for whole IgG
by ELISA on BPN' Y217L coated plates, titers were calcu-
latedBMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/2
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group of four animals was immunized every two weeks,
immediately after the removal of a serum sample. There
were a total of six immunizations. The first immunization
was in Complete Freund's Adjuvant. Incomplete Freund's
Adjuvant was used for all subsequent immunizations.
Each immunogen was provided as a stock solution at 20
mg/ml in 20 mM sodium acetate, 1 mM calcium chloride,
and was diluted to 1,5,10, or 20 µg/ml in cold DPBS to a
total volume of 1 ml. This was emulsified at a 1:1 ratio
with CFA or IFA. Each guinea pig was immunized subcu-
taneously with a total of 500 µl of emulsion.
2. Priming study with BPN' Y217L and GP002
Guinea pig immunizations were out-sourced to EL Labs in
Santa Cruz, CA. The following immunization protocol
was followed: four groups of four Hartley guinea pigs were
distinguished as groups A through D. All animals received
5 µg of immunogen. The first immunization was per-
formed in CFA, then IFA for all subsequent immuniza-
tions. Each animal received a total of 500 µl of emulsion.
All immunizations were performed subcutaneously using
the following schedule: First immunization – Group A re-
ceived BPN' Y217L, groups B-D GP002. Week two –
Groups A and B received BPN' Y217L, Groups B and C re-
ceived GP002. Week 4 – Groups A through C received
BPN' Y217L, Group D received GP002. Serum samples
were drawn at week 6.
3. T-cell epitope mapping for GP002 and BPN' Y217L
Guinea pig immunizations were outsourced to Strategic
BioSolutions, Ramona, CA. Groups of 10 female Hartley
strain guinea pigs were immunized every two weeks with
5 ug per dose of BPN' Y217L or GP002 in Complete Fre-
und's adjuvant, then Incomplete Freund's as described
above. Two weeks following the third immunization, an-
imals were sacrificed and their spleens and serum samples
collected.
ELISA protocols (whole protein IgG)
Medium binding EIA plates (Costar, Cambridge, MA)
were coated with 10 µg/ml of acid-denatured enzyme in
DPBS. Enzyme was coated onto the plates at 4°C over-
night. Plates were then washed three times with PBS/
0.25% Tween-20 (Sigma, St. Louis, MO). Plates were
blocked with 1% BSA (Rockland, Gilbertsville, PA)/PBS at
room temperature for 30 minutes. Ten-fold serial dilution
of sera in 1% BSA/PBS were performed. The plates were
covered and incubated at room temperature for two
hours. Secondary biotin anti-IgG antibody (guinea pig
IgG Fc specific, Jackson ImmunoResearch, West Grove,
PA) was diluted 1:10,000 in 1%BSA/PBS. 100 µl of this di-
lution were placed per well on the plates. The plates were
again covered and incubated at room temperature for 1
hour. Plates were washed (as above). Avidin-HRP (Jack-
son ImmunoResearch) was diluted 1:1000 in 1%BSA/PBS
and 100 µl per well were added to the plates. Plates were
covered and incubated at room temperature for 30 min-
utes. The plates were washed (as above). The ELISAs were
developed with ABTS in citrate buffer with 0.03% H2O2,
at room temperature for 40 minutes and then read at OD
= 405 nm. Titers were found by using a log-based slope
equation where the O.D. = 0.5.
Peptides
1. Proliferation assays: 15-mer peptides offset by 3 amino
acids describing the proteins of interest were obtained as
a Pep Set from Mimotopes (San Diego, CA). Pep Sets were
constructed for Bacillus lentus subtilisin (B. lentus subtili-
sin) and Bacillus amyloliqufaciens subtilisin (subtilisin
BPN' Y217L). Peptides were resuspended in DMSO at 1
mM.
2. Linear epitopes: Biotinylated 15-mer peptides from ob-
tained from Mimotopes (San Diego, CA). The 15-mer
peptides were offset by 5 amino acids, and described the
sequence of BPN' Y217L. The biotin moiety at the N-ter-
minus was separated from the peptide sequence of inter-
est by a 4 amino acid spacer. Biotinylated peptides were
resuspended at 1 mM in DMSO.
T-cell epitope mapping of enzymes B. lentus subtilisin, 
BPN' Y217L and GP002
T cell epitope mapping was performed using splenocytes
from immunized Hartley strain guinea pigs. Splenocytes
from immunized guinea pigs were resuspended in AIM-V
(Life Technologies Gaithersberg, MD) containing 100
units/ml penicillin, 100 ug/ml streptomycin, 1 mM
glutamine, and either 10% autologous serum or 10% FCS
(Sigma, St. Louis, MO). Using round-bottom 96 well
plates (Costar, Cambridge, MA), either 5 ×  105 or 1 ×  106
cells/well in 200 uL of media. 5 uM of peptide were placed
in each well. Each peptide was tested minimally in dupli-
cate. DMSO was present at 0.5%. Control cultures con-
tained 0.5% DMSO in the absence of peptide. The
cultures were incubated at 37°C for 5 days. On day 5, cells
were pulsed with tritiated thymidine at a concentration of
0.5 µCi/well. On day 6, cells were harvested and counted.
A proliferative response was counted as positive if the av-
erage counts for a particular peptide were three times
higher than the control levels.
Linear B-cell epitope mapping of enzymes BPN' Y217L and 
GP002
Biotinylated peptides were resuspended in 1 ml of DMSO
(1 mM). A stock plate was made by diluting 10 µl of each
peptide into 200 µl of PBS/ 0.025% Tween-20 (Sigma, St.
Louis, MO). Streptavidin-coated plates (Pierce, Rockford,
IL) were blocked with 1%BSA/PBS for 30 minutes at room
temperature. Approximately 5 µM of biotinylated peptide
was coated onto each well. Each peptide was tested mini-BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/2
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mally in duplicate. Plates were incubated for one hour at
room temperature and then washed three times. Guinea
pig serum was diluted 1:1000 in PBS/Tween-20. 100 µl of
dilute sera was placed into each well and plates were incu-
bated at room temperature for one hour and then washed
three times. The secondary antibody, anti-guinea pig IgG-
HRPO) (Jackson ImmunoResearch, West Grove, PA) was
diluted 1:1000 in 1%BSA/PBS and 100 µl of dilute conju-
gate was added to each well. Plates were incubated at
room temperature for 1 hour and then washed three times
in PBS/Tween-20. Plates were then washed twice in PBS
only. ELISAs were developed using ABTS in citrate buffer,
0.03% H2O2. Plates were then incubated at room temper-
ature for up to 45 minutes and then read at 405 nm. OD
readings for each peptide were compared to background
readings with no peptide. Any peptide giving readings at
least twice the background was considered a positive.
References
1. Ingulli E, Mondino A, Khoruts A, Jenkins MK: In vivo detection of
dendritic cell antigen presentation to CD4(+) T cells. J Exp
Med 1997, 185(12):2133-41
2. Schlienger K, Craighead N, Lee KP, Levine BL, June CH: Efficient
priming of protein antigen-specific human CD4(+) T cells by
monocyte-derived dendritic cells. Blood 2000, 96(10):3490-8
3. Steinman RM: The dendritic cell system and its role in immu-
nogenicity. Annu Rev Immunol 1991, 9:271-96
4. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK:
Visualization of specific B and T lymphocyte interactions in
the lymph node. Science 1998, 281(5373):96-9
5. Parker DC: T cell-dependent B cell activation. Annu Rev Immunol
1993, 11:331-60
6. Smith KM, Pottage L, Thomas ER, Leishman AJ, Doig TN, Xu D, Liew
FY, Garside P: Th1 and Th2 CD4+ T cells provide help for B
cell clonal expansion and antibody synthesis in a similar man-
ner in vivo. J Immunol 2000, 165(6):3136-44
7. Ahlborg N, Nardin EH, Perlmann P, Berzins K, Andersson R: Immu-
nogenicity of chimeric multiple antigen peptides based on
Plasmodium falciparum antigens: impact of epitope orienta-
tion. Vaccine 1998, 16(1):38-44
8. Partidos C, Stanley C, Steward M: The effect of orientation of
epitopes on the immunogenicity of chimeric synthetic pep-
tides representing measles virus protein sequences. Mol Im-
munol 1992, 29(5):651-8
9. Partidos C, Stanley C, Steward M: The influence of orientation
and number of copies of T and B cell epitopes on the specif-
icity and affinity of antibodies induced by chimeric peptides.
Eur J Immunol 1992, 22(10):2675-80
10. Denton G, Hudecz F, Kajtar J, Murray A, Tendler SJ, Price MR: Se-
quential order of T and B cell epitopes affects immunogenic-
ity but not antibody recognition of the B cell epitope. Pept Res
1994, 7(5):258-64
11. Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appella E, Chisari
FV, Guidotti LG, Chesnut RW, Livingston B, et al: The optimization
of helper T lymphocyte (HTL) function in vaccine develop-
ment. Immunol Res 1998, 18(2):79-92
12. Reece JC, Geysen HM, Rodda SJ: Mapping the major human T
helper epitopes of tetanus toxin. The emerging picture. Jour-
nal of Immunology 1993, 151(11):6175-84
13. Adorini L, Appella E, Doria G, Nagy ZA: Mechanisms influencing
the immunodominance of T cell determinants.  J Exp Med
1988, 168(6):2091-104
14. del Guercio MF, Alexander J, Kubo RT, Arrhenius T, Maewal A, Ap-
pella E, Hoffman SL, Jones T, Valmori D, Sakaguchi K, et al: Potent
immunogenic short linear peptide constructs composed of B
cell epitopes and Pan DR T helper epitopes (PADRE) for an-
tibody responses in vivo. Vaccine 1997, 15(4):441-8
15. Franke ED, Hoffman SL, Sacci JB Jr, Wang R, Charoenvit Y, Appella E,
Chesnut R, Alexander J, Del Guercio MF, Sette A: Pan DR binding
sequence provides T-cell help for induction of protective an-
tibodies against Plasmodium yoelii sporozoites. Vaccine 1999,
17(9-10):1201-5
16. Shi YP, Hasnain SE, Sacci JB, Holloway BP, Fujioka H, Kumar N, Wohl-
hueter R, Hoffman SL, Collins WE, Lal AA: Immunogenicity and in
vitro protective efficacy of a recombinant multistage Plas-
modium falciparum candidate vaccine. Proc Natl Acad Sci USA
1999, 96(4):1615-20
17. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A,
Snoke K, Serra HM, Kubo RT, Sette A, et al: Development of high
potency universal DR-restricted helper epitopes by modifi-
cation of high affinity DR-blocking peptides. Immunity 1994,
1(9):751-61
18. Kobayashi H, Wood M, Song Y, Appella E, Celis E: Defining promis-
cuous MHC class II helper T-cell epitopes for the HER2/neu
tumor antigen. Cancer Res 2000, 60(18):5228-36
19. van der Burg SH, Kwappenberg KM, Geluk A, van der Kruk M, Pon-
tesilli O, Hovenkamp E, Franken KL, van Meijgaarden KE, Drijfhout
JW, Ottenhoff TH, et al: Identification of a conserved universal
Th epitope in HIV-1 reverse transcriptase that is processed
and presented to HIV-specific CD4+ T cells by at least four
unrelated HLA-DR molecules. J Immunol 1999, 162(1):152-60
20. Pachuk CJ, McCallus DE, Weiner DB, Satishchandran C: DNA vac-
cines-challenges in delivery. Curr Opin Mol Ther 2000, 2(2):188-98
21. Rolph MS, Kaufmann SH: CD40 Signaling Converts a Minimally
Immunogenic Antigen into a Potent Vaccine Against the In-
tracellular Pathogen Listeria monocytogenes. J Immunol 2001,
166(8):5115-21
22. Smith SG: The polyepitope approach to DNA vaccination. Curr
Opin Mol Ther 1999, 1(1):10-5
23. Yang W, Jackson DC, Zeng Q, McManus DP: Multi-epitope schis-
tosome vaccine candidates tested for protective immuno-
genicity in mice. Vaccine 2000, 19(1):103-13
24. Good MF, Kaslow DC, Miller LH: Pathways and strategies for de-
veloping a malaria blood-stage vaccine. Annu Rev Immunol 1998,
16:57-87
25. Hansson M, Nygren PA, Stahl S: Design and production of re-
combinant subunit vaccines. Biotechnol Appl Biochem 2000, 32(Pt
2):95-107
26. Siezen RJ, Leunissen JA: Subtilases: the superfamily of subtilisin-
like serine proteases. Protein Sci 1997, 6(3):501-23
27. Wells JA, Cunningham BC, Graycar TP, Estell DA: Recruitment of
substrate-specificity properties from one enzyme into a re-
lated one by protein engineering. Proc Natl Acad Sci U S A 1987,
84(15):5167-71
28. Robinson MK, Horn PA, Kawabata TT, Babcock LS, Fletcher ER, Sarlo
K: Use of the mouse intranasal test (MINT) to determine the
allergenic potency of detergent enzymes: comparison to the
guinea pig intratracheal (GPIT) test. Toxicol Sci 1998, 43(1):39-
46
29. Sarlo K, Fletcher R, Gaines W, Ritz HL: Respiratory allergenicity
of detergent enzymes in the guinea pig intratracheal test: as-
sociation with sensitization of occupationally exposed indi-
viduals. Fundamental and Applied Toxicology 1997, 39(1):44-52
30. Hewitt CRA, Brown AP, Hart BJ, Pritchard DI: A major house dust
mite allergen disrupts the immunoglobulin E network by se-
lectively cleaving CD23: Innate protection by antiproteinas-
es. Journal of Experimental Medicine 1995, 182:1537-44
31. Schultz O, Sewell H, Shakib F: Proteolytic cleavage of CD25, the
a subunit of the human T cell interleukin 2 receptor, by Der
p 1, a major mite allergen with cysteine protease activity.
Journal od Experimental Medicine 1998, 187(2):271-5
32. Schuiz O, Sutton BJ, Beaul RL, Shi J, Sewell HF, Gould HJ, Laing P,
Shakib F: Cleavage of the low-affinity receptor for human IgE
(CD23) by a mite cysteine protease: nature of the cleaved
fragment in relation to the structure and function of CD23.
European Journal of Immunology 1997, 27(3):584-8
33. Falcone FH, Haas H, Gibbs BF: The human basophil: a new ap-
preciation of its role in immune responses.  Blood 2000,
96(13):4028-38
34. Bjerke T, Gaustadnes M, Nielsen S, Nielsen LP, Schiotz PO, Rudiger
N, Reimert CM, Dahl R, Christensen I, Poulsen LK: Human blood
eosinophils produce and secrete interleukin 4.  Respir Med
1996, 90(5):271-7
35. Sun G, Stacey MA, Schmidt M, Mori L, Mattoli S: Interaction of mite
allergens Der p3 and Der p9 with protease-activated recep-BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/2
Page 12 of 12
(page number not for citation purposes)
tor-2 expressed by lung epithelial cells.  J Immunol 2001,
167(2):1014-21
36. Sarlo K, Ritz HL, Fletcher ER, Schrotel KR, Clark ED: Proteolytic
detergent enzymes enhance the allergic antibody response
of guinea pigs to nonproteolytic detergent enzymes in a mix-
ture: implications for occupational exposure. Journal of Allergy
and Clinical Immunology 1997, 100(4):480-7
37. Tsujihata Y, So T, Chijiiwa Y, Hashimoto Y, Hirata M, Ueda T, Imoto
T: Mutant mouse lysozyme carrying a minimal T cell epitope
of hen egg lysozyme evokes high autoantibody response. J Im-
munol 2000, 165(7):3606-11
38. Dalum I, Butler DM, Jensen MR, Hindersson P, Steinaa L, Waterston
AM, Grell SN, Feldmann M, Elsner HI, Mouritsen S: Therapeutic an-
tibodies elicited by immunization against TNF-alpha. Nat Bio-
technol 1999, 17(7):666-9
39. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman
S, Kubo RT, Chesnut RW, Grey HM, Sette A: Several common
HLA-DR types share largely overlapping peptide binding
repertoires. J Immunol 1998, 160(7):3363-73
40. Constant S, Pfeiffer C, Woodard A, Pasqualini T, Bottomly K: Extent
of T cell receptor ligation can determine the functional dif-
ferentiation of naive CD4+ T cells. Journal of Experimental Medi-
cine 1995, 182(5):1591-6
41. Constant SL, Bottomly K: Induction of Th1 and Th2 CD4+ T cell
responses: the alternative approaches. Annu Rev Immunol 1997,
15(9):297-322
42. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA,
Weiner HL, Nabavi N, Glimcher LH: B7-1 and B7-2 Costimulato-
ry Molecules Activate Differentially the Th1/Th2 Develop-
mental Pathways: Application to Autoimmune Disease
Therapy. Cell 1995, 80:707-18
43. Leitenberg D, Boutin Y, Constant S, Bottomly K: CD4 regulation of
TCR signalling and T cell differentiation following stimula-
tion with peptides of different affinities for the TCR. Journal of
Immunology 1998, 161(3):1194-203
44. Murray JS: How the MHC selects Th1/Th2 immunity. Immunol-
ogy Today 1998, 19(4):157-63
45. Perez VL, Lederer JA, Lictman AH, Abbas AK: Stability of Th1 and
Th2 populations. International Immunology 1995, 7(5):869-75
46. Rogers PR, Croft M: Peptide dose, affinity, and time of differen-
tiation can contribute to the Th1/Th2 cytokine balance. Jour-
nal of Immunology 1999, 163:1205-13
47. Schountz T, Kasselman JP, Martinson FA, Brown L, Murray JS: MHC
genotype controls the capacity of ligand density to switch T
helper (Th)-1/Th-2 priming in vivo. Journal of Immunology 1996,
157(9):3893-901
48. Schweitzer AN, Borriello F, Wong RCK, Abbas AK, Sharpe AH: Role
of costimulators in T cell differentiation: Studies using anti-
gen-presenting cells lacking expression of CD80 or CD86.
Journal of Immunology 1997, 158:2713-22
49. Schweitzer AN, Sharpe AH: Studies using antigen-presenting
cells lacking expression of both B7-1 (CD80) and B7-2
(CD86) show distinct requirements for B7 molecules during
priming versus restimulation of Th2 but not Th1 cytokine
production. Journal of Immunology 1998, 161:2762-71
50. Tao X, Constant S, Jorritsma P, Bottomly K: Strength of TCR sig-
nal determines the costimulatory requirements for Th1 and
Th2 CD4+ T cell differentiation.  Journal of Immunology 1997,
15(12):5956-63
51. Schneider SC, Ohmen J, Fosdick L, Gladstone B, Guo J, Ametani A,
Sercarz EE, Deng H: Cutting edge: introduction of an en-
dopeptidase cleavage motif into a determinant flanking re-
gion of hen egg lysozyme results in enhanced T cell
determinant display. J Immunol 2000, 165(1):20-3
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com